Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 30, Number 7—July 2024
Dispatch

Rocky Mountain Spotted Fever Mimicking Multisystem Inflammatory Syndrome in Hospitalized Children, Sonora, Mexico

Gerardo Álvarez-HernándezComments to Author , Cristian N. Rivera-Rosas, J.R. Tadeo Calleja-López, David W. McCormick, Christopher D. Paddock, Jehan Bonizú Álvarez-Meza, and Fabián Correa-Morales
Author affiliations: University of Sonora, Hermosillo, Mexico (G. Álvarez-Hernández, C.N. Rivera-Rosas, J.R.T. Calleja-López); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (D.W. McCormick, C.D. Paddock); Sonora Children’s Hospital, Hermosillo (J.B. Álvarez-Meza); Centro Nacional de Programas Preventivos y Control de Enfermedades, Mexico City, Mexico (F. Correa-Morales)

Main Article

Table 2

Medical therapies and selected characteristics of patients in study of Rocky Mountain spotted fever mimicking multisystem inflammatory syndrome in hospitalized children, Sonora, Mexico*

Case no. IVIg Corticosteroid Anticoagulation prophylaxis Vasopressor or inotrope First outpatient medical consultation, d† Treatment delay, d‡ Hospital care, d
1
 1 g/kg, day 1; 2 g/kg, day 2
 Methylprednisolone IV, 30 mg/kg/dose; dexamethasone IV, 8 mg/d
 Enoxaparin, 0.5 mg/kg/dose
 Dobutamine, 5 µg/kg/min; norepinephrine, 0.05 µg/kg/min
 1
 13
 15
2
 NA
 Hydrocortisone IV, 4 mg/kg/d; methylprednisolone IV, 1 g/d
 NA
 Dobutamine, 5 µg/kg/min; norepinephrine, 0.1 µg/kg/min
 1
 6
 4
3
 1 g/kg/day for 2 d
 Methylprednisolone IV, 1 mg/kg/d; dexamethasone IV, 0.2 mg/kg/dose; hydrocortisone IV, 2 mg/kg/dose
 Enoxaparin SC, 0.5 mg/kg/dose; aspirin by mouth, 60 mg/kg/d
 Norepinephrine, 0.22 µg/kg/min
 3
 3
 15
4
 NA
 Hydrocortisone IV, 1 mg/kg/dose
 NA
 Norepinephrine, 0.22 µg/kg/min; dobutamine, 8.3 µg/kg/min
 1
 10
 13
5 1 g/kg/day for 2 d Methylprednisolone IV, 1 mg/kg/d; prednisone PO, 1 mg/kg/d Enoxaparin SC, 0.5 mg/kg/dose NA 3 10 4

*IV, intravenous; IVIg, intravenous immunoglobulin; NA, not applicable; SC, subcutaneous. †Number of days until first outpatient medical consultation after symptom onset. ‡Delay in doxycycline treatment after symptom onset; doxycycline was initiated at the time RMSF was clinically suspected during the hospital stay.

Main Article

Page created: June 06, 2024
Page updated: June 22, 2024
Page reviewed: June 22, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external